Search

Xiaozhu D Duan

from Alameda, CA
Age ~58
Get Report
Also known as:
Xiaozhu D Liu, Xiaozhu Dun
Phone and address:
208 Galway Bay, Alameda, CA 94502
(510) 521-2982
Related to:
Yan Ming Li, 65Xiao A Duan, 67Daniel S Liu, 30Zhao Li Yan, 60Kassidy Y Li, 45Yanli Li, 59Xiao H Duan, 56Liu Pu, 89Sue DuanMingsong Dr Liu, 61Liu Pu Yang, 89
Connected to:
Biao Duan, 56Bin Duan, 69Christine Duan, 34Gerald F Duan, 68Jining Duan, 56Jun Duan, 54Kevin Duan, 30Lele Duan, 43Leo J Duan, 62Lisha Duan, 33

Xiaozhu Duan Phones & Addresses

  • 208 Galway Bay, Alameda, CA 94502 (510) 521-2982
  • 601 Carlitos Ave, North Las Vegas, NV 89031
  • 7733 Via Paseo Ave, Las Vegas, NV 89128
  • Orlando, FL
  • Ames, IA
  • San Francisco, CA
  • Cold Spring Harbor, NY
  • Huntington Station, NY

Resumes

Resumes

Xiaozhu Duan Photo 1

Scientist At Diadexus

View page
Position:
Scientist at Diadexus
Location:
San Francisco Bay Area
Industry:
Broadcast Media
Work:
Diadexus
Scientist
Skills:
Biotechnology
Xiaozhu Duan Photo 2

Xiaozhu Duan

View page
Location:
San Francisco Bay Area
Industry:
Biotechnology
Education:
Sichuan University
Skills:
ELISA
Biotechnology
Molecular Biology
Lifesciences
Biochemistry

Publications

Us Patents

Cln101 Antibody Compositions And Methods Of Use Alone And In Combination With Prostate Specific Antigen And Other Cancer Markers

View page
US Patent:
20070183969, Aug 9, 2007
Filed:
Jun 1, 2004
Appl. No.:
10/558543
Inventors:
Xiaozhu Duan - Alameda CA, US
Nam Kim - Santa Clara CA, US
Robert Wolfert - Palo Alto CA, US
International Classification:
A61K 51/00
A61K 39/395
G01N 33/574
C07K 16/30
C07K 16/46
US Classification:
424001110, 435007230, 424155100, 424178100, 530391100, 530388800
Abstract:
This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (Cln101) antibodies that bind to Cln101 in vivo. The invention also encompasses compositions comprising an anti-Cln101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Cln101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Cln101 antibodies. The invention encompasses a method of producing the anti-Cln10I antibodies. Other aspects of the invention are a method of killing an Cln101-expressing cancer cell, comprising contacting the cancer cell with an anti-Cln101 antibody and a method of alleviating or treating an Cln101-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Cln101 antibody to the mammal.

Cln101 Antibody Compositions And Methods Of Use Alone And In Combination With Prostate Specific Antigen And Other Cancer Markers

View page
US Patent:
20100003705, Jan 7, 2010
Filed:
Jun 8, 2009
Appl. No.:
12/480033
Inventors:
Xiaozhu Duan - Alameda CA, US
Nam Kim - Santa Clara CA, US
Robert L. Wolfert - Palo Alto CA, US
International Classification:
G01N 33/574
US Classification:
435 723
Abstract:
This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (Cln101) antibodies that bind to Cln101 in vivo. The invention also encompasses compositions comprising an anti-Cln101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Cln101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Cln101 antibodies. The invention encompasses a method of producing the anti-Cln101 antibodies. Other aspects of the invention are a method of killing an Cln101-expressing cancer cell, comprising contacting the cancer cell with an anti-Cln101 antibody and a method of alleviating or treating an Cln101-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Cln101 antibody to the mammal.
Control profile
Xiaozhu D Duan from Alameda, CA, age ~58 Get Report